GLOBAL PULMONARY DRUG DELIVERY MARKET FORECAST 2019-2028

GLOBAL PULMONARY DRUG DELIVERY MARKET FORECAST 2019-2028

  • August 2020 •
  • 248 pages •
  • Report ID: 5953909 •
  • Format: PDF
KEY FINDINGS
The global pulmonary drug delivery market is anticipated to register a CAGR of 5.06%, during the forecast years of 2019 to 2028. The key drivers, such as advancements in technology, the surging prevalence of respiratory diseases, and the rising geriatric population, are attributed to market growth.

MARKET INSIGHTS
With its recent introduction into the pharmaceutical field, pulmonary drug delivery systems are used to treat both local as well as systemic types of lung diseases.They are characterized by their ability to directly deliver medication to the designated location in the body or other distant sites through the bloodstream.

Moreover, different forms of drug delivery systems, including inhalers and nebulizers, were introduced as alternative treatments for diverse lung conditions.
Technology plays a crucial role in daily lives, and is consistently evolving.As a result, the rising demand for innovative products, incorporated with changing lifestyles, the need for convenience, and better facilities, leads to technological developments.

Similarly, the market for pulmonary drug delivery is fuelled by rising advancements in technology, and is projected to generate potential growth opportunities. The limitations of conventional treatments, such as low efficacy and delayed onset of action, are also predicted to encourage the development of innovative and superior targeted drug delivery systems.

REGIONAL INSIGHTS
The global pulmonary drug delivery market growth is geographically analyzed through the Asia Pacific, Europe, North America, and the rest of the world.The Asia Pacific is projected to be the fastest-growing region, owing to the high incidence of chronic obstructive pulmonary disease (COPD), indicating significant socioeconomic problems.

The rising number of patients with allergic rhinitis and asthma also contributes to the region’s market growth.

COMPETITIVE INSIGHTS
The market is competitive, with major players engaged in constant product developments, in addition to partnership agreements to ease market penetration.Moreover, the growing number of dealers and distributors is predicted to intensify the industry rivalry, in the upcoming years.

Leading companies operating in the market include, Boehringer Ingelheim GmbH, 3M Company, GlaxoSmithKline PLC, Koninklijke Philips NV, AstraZeneca PLC, etc.

Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Companies mentioned
1. 3M COMPANY
2. ACTELION PHARMACEUTICALS LTD
3. AEROGEN
4. AGILENT TECHNOLOGIES INC
5. ASTRAZENECA PLC
6. BOEHRINGER INGELHEIM GMBH
7. CLEMENT CLARKE INTERNATIONAL
8. GF HEALTH PRODUCTS INC
9. GLAXOSMITHKLINE PLC
10. KONINKLIJKE PHILIPS NV
11. MERCK & CO INC
12. NOVARTIS AG
13. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
14. VECTURA GROUP PLC